A Retrospective Cohort Study of Kawasaki Disease in Hue Central Hospital for 10 Years (2010-2019)

  • Ngo Minh Xuan Department of Pediatrics, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
  • Tran Kiem Hao Pediatric Center, Hue Central Hospital, Hue, Vietnam
  • Nguyen Thi Hoang Anh Pediatric Center, Hue Central Hospital, Hue, Vietnam
Keywords: Kawasaki disease, Gammaglobulin, Complication

Abstract

INTRODUCTION: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology which affects mainly children <5 years of age. If the disease is left untreated, it can lead to serious complications such as inflammation of the blood vessels.

AIM: We aim to evaluate the clinical and laboratory findings and response to therapy of KD at Hue Central Hospital.

METHODS: This is a retrospective study of patients with KD at Pediatric Center of Hue Central Hospital between January 2010 and December 2019. Clinical and laboratory examinations as well as the echocardiograms finding were analyzed.

RESULTS: All patients were under 5 years old, in which boys were more than girls. Fever lasting over 5 days, changing in the mouth mucosa, and peripheral extremities were seen in all patients. About 73.2% had bilateral conjunctivitis and 78.0% had rash. About 42.3% of patients had cervical lymphadenopathy. Laboratory findings were noted with 84.5% of patients had hyperleukocytosis (>12,000/ mm3), 76.2% of patients had high serum C-reactive protein (CRP) levels (>100 mg/dl), 56% of patients had erythrocyte sediment rate >60 mm in the 1st h, and 34.5% of patients had thrombocytosis (platelet count >500,000/mm3) at the time of diagnosis. About 26.2% of patients had coronary artery lesions. Most patients (84.4%) had good outcome since the first dose of gamma-globulin and 13% of patients needed the second dose. There was a significant correlation between coronary artery abnormalities and no or late treatment of gamma-globulin.

CONCLUSION: KD was very common in children under 5 years old with the high rate of coronary artery lesion. Treatment with gamma-globulin on or before 10 days of fever resulted in better coronary outcomes and decreased the total length of time of clinical symptoms.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kawasaki T, Naoe S. History of Kawasaki disease. Clin Exp Nephrol. 2014;18(2):301-4. https://doi.org/10.1007/ s10157-013-0877-6

PMid:24595558

Lin MT, Wu MH. The global epidemiology of Kawasaki disease: Review and future perspectives. Glob Cardiol Sci Pract. 2017;2017(3):e201720. PMid:29564341

Advani N, Sastroasmoro S, Ontoseno T, Uiterwaal CS. Long-term outcome of coronary artery dilatation in Kawasaki disease. Ann Pediatr Cardiol. 2018;11(2):125-9. https://doi.org/10.4103/ apc.apc_172_16 PMid:29922008

Nichols L, Lagana S, Parwani A. Coronary artery aneurysm: A review and hypothesis regarding etiology. Arch Pathol Lab Med. 2008;132(5):823-8. PMid:18466032

Viet PH. Clinical features, laboratory investigation and cardiovascular abnormalities in children with Kawasaki disease. Vietnam Med J. 2019;7(3):125-9.

Cox JR, Sallis RE. Recognition of Kawasaki disease. Perm J. 2009;13(1):57-61. PMid:21373247

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):e927-e999. https://doi.org/10.1161/ cir.0000000000000484

GundoÄŸdu F, Arslan S, Buyukkaya E, Senocak H. Treatment of a coronary artery aneurysm by use of a covered stent graft a case report. Int J Angiol. 2007;16(1):31-2. https://doi. org/10.1055/s-0031-1278242 PMid:22477247

Sakulchit T, Benseler SM, Goldman RD. Acetylsalicylic acid for children with Kawasaki disease. Can Fam Physician. 2017;63(8):607-9. PMid:28807954

Gerding R. Kawasaki disease: A review. J Pediatr Health Care. 2011;25(6):379-87. PMid:22018429

Lang B. Recognizing Kawasaki disease. Paediatr Child Health. 2001;6(9):638-43. PMid:20084135

Lin YT, Manlhiot C, Ching JC, Han RK, Nield LE, Dillenburg R, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int. 2010;52(5):699-706. https://doi.org/10.1111/j.1442-200x.2010.03092.x PMid:20113416

Singh-Grewal D, Wong M, Isaacs D. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: A review of three years experience. J Paediatr Child Health. 2005;41(9-10):495-9. https://doi. org/10.1111/j.1440-1754.2005.00690.x PMid:16150066

Sánchez-Manubens J, Antón J, Bou R, Iglesias E, Calzada- Hernandez J, Kawasaki Disease in Catalonia Working Group. Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S139-44. https://doi.org/10.1186/1546-0096-12-s1-p123 PMid:26939753

Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: Surveillance from national hospitalization records. Eur J Pediatr. 2017;176(8):1061-5. https://doi.org/10.1007/s00431-017-2947-3 PMid:28612175

Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133(4):e1009-14. https:// doi.org/10.1542/peds.2013-2936 PMid:24685950

Chen JJ, Ma XJ, Liu F, Yan WL, Huang MR, Huang M, et al. Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012. Pediatr Infect Dis J. 2016;35(1):7-12. PMid:26372452

Son MB, Newburger JW. Kawasaki disease. Pediatr Rev. 2018;39(2):78-90. PMid:29437127

Abe J. Immunological aspects of Kawasaki disease. Nihon Rinsho. 2008;66(2):267-71. PMid:18265455

Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30(12):1022-6. https://doi.org/10.1097/inf.0b013e31822d4f56 PMid:21817952

Fernandez-Cooke E, Barrios Tascón A, Sánchez-Manubens J, Antón J, Grasa Lozano CD, Aracil Santos J, et al. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group. PLoS One. 2019;14(5):e0215665. https://doi.org/10.1371/journal.pone.0215665 PMid:31107862

Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055-8. https://doi. org/10.1016/s0140-6736(84)91504-6 PMid:6209513

Published
2020-04-10
How to Cite
1.
Xuan NM, Kiem Hao T, Hoang Anh NT. A Retrospective Cohort Study of Kawasaki Disease in Hue Central Hospital for 10 Years (2010-2019). Open Access Maced J Med Sci [Internet]. 2020Apr.10 [cited 2020Oct.26];8(B):99-103. Available from: https://www.id-press.eu/mjms/article/view/3858